Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
Data Hub
Contact
Privacy PolicySuccessful 8th Steering Committee Meeting in Heidelberg
From 13-14 October 2022, the WP leaders of MICROB-PREDICT met at EMBL in Heidelberg to discuss latest results and next steps for biomarker validation and the start of the ALB-Trial. We look forward to an exciting 2nd half of the project!
More newsThe Liver Meeting
After two long years, it's time to reconnect with your peers! Come see the who's who of experts at The Liver Meeting this year at the Walter E. Washington Convention Center, in Washington, DC from 04 – 08 November 2022. Find more information here.
More events